Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)

Boehringer Ingelheim

Status: Completed

Conditions: Prostatic Hyperplasia

Treatments: Drug: Secotex®

Study type: Observational

Funder types: Industry

Identifiers

NCT02244346

527.58

Details and patient eligibility

About

Study to evaluate the safety profile of Secotex® in the improvement of the symptoms of Benign Prostatic Hyperplasia in real clinical practice

Enrollment: 811 patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients of any age with a diagnosis of symptomatic Benign Prostatic Hyperplasia (BPH)
• Patients with symptoms, that according to physician require medical treatment to improve quality of life
• Patients could be naive to treatment or could be on treatment with other drugs but have not responded adequately to treatment

Exclusion criteria

• Patients with known hypersensitivity to Tamsulosin, or any other component of the product
• Patients with a history of orthostatic hypotension or severe liver failure

Trial design

811 participants in 1 patient group

Benign prostatic hyperplasia patients

Treatment:

Drug: Secotex®